Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 22, 2025 08:44 ET | Source: Sixty Degrees Pharmaceuticals

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

60 Degrees Pharma survey suggests babesiosis affects up to 3M Americans—vastly more than CDC data—and may underlie millions of chronic fatigue cases.
August 15, 2023 07:31 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov

ACLR8-LR, a double-blind, randomized, placebo-controlled Phase IIB study to determine efficacy of the ARAKODA® regimen of tafenoquine in COVID-19 patients with mild-moderate symptoms and low risk of...
July 31, 2023 07:59 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects

Patent provides exclusive use of tafenoquine for prevention of malaria in malaria-naive individuals in Canada until late 2035.Tafenoquine is the active molecule in 60 Degrees Pharmaceuticals’...
July 14, 2023 12:39 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces Closing of Initial Public Offering

WASHINGTON, July 14, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc., (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), specialists in developing and marketing medicines for infectious...
July 12, 2023 12:29 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces Pricing of Initial Public Offering

WASHINGTON, July 12, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc., (NASDAQ: SXTP; SXTPW) ("60P" or the "Company"), specialists in developing and marketing medicines for infectious...
April 26, 2023 07:34 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Awarded U.S. Patent Covering Tafenoquine for Treatment of COVID-19 and Other Lung Infections

Patent provides exclusive use through 2040 of tafenoquine for treatment of COVID-19 and other lung infections. Tafenoquine is the active molecule in 60P’s FDA-approved drug for malaria prevention,...